Maat Pharma SA
PAR:MAAT
Maat Pharma SA
Retained Earnings
Maat Pharma SA
Retained Earnings Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Retained Earnings | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
M
|
Maat Pharma SA
PAR:MAAT
|
Retained Earnings
-€18.1m
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
Valneva SE
PAR:VLA
|
Retained Earnings
-€448.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Innate Pharma SA
PAR:IPH
|
Retained Earnings
-€361.3m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-14%
|
||
G
|
Genfit SA
PAR:GNFT
|
Retained Earnings
-€361.2m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-23%
|
|
Inventiva SA
PAR:IVA
|
Retained Earnings
-€281.4m
|
CAGR 3-Years
-76%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Eurobio Scientific SA
PAR:ALERS
|
Retained Earnings
€155.2m
|
CAGR 3-Years
20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Maat Pharma SA
Glance View
Maat Pharma SA operates as a clinical-stage microbiome therapeutics company. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 43 full-time employees. The company went IPO on 2021-11-08. The firm specializes in the microbiome therapy that is aimed to treatment of Gut Microbiota alteration (Dysbiosis) using patient-specific biotherapeutics in patients with serious medical conditions. Its MaaT Microbiome Restoration Therapy (MMRB) discovery and analysis platform supports the evaluation of drug candidates, the determination of new disease targets and the identification of biomarkers for microbiome-related conditions.
See Also
What is Maat Pharma SA's Retained Earnings?
Retained Earnings
-18.1m
EUR
Based on the financial report for Dec 31, 2023, Maat Pharma SA's Retained Earnings amounts to -18.1m EUR.
What is Maat Pharma SA's Retained Earnings growth rate?
Retained Earnings CAGR 5Y
-10%
Over the last year, the Retained Earnings growth was -45%. The average annual Retained Earnings growth rates for Maat Pharma SA have been -57% over the past three years , -10% over the past five years .